Skip to content
Brand AI

Walvax Biotechnology

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2018

    Walvax three times subject to regulatory measures by securities regulator

    Walvax Biotechnology received a warning letter from the Yunnan Securities Regulatory Bureau in 2018 over major discrepancies in its earnings forecast and failure to disclose a major shareholder's share pledge, among other issues; in 2021 it was ordered to rectify because of inadequate investment decisions and post-investment management; in 2025 it was again ordered to rectify because directors' and senior executives' compensation had not gone through statutory review procedures, and the Shenzhen Stock Exchange issued a regulatory letter. Ordered to rectify and recorded in the integrity file.

    Source